Superseded public profile

FDA-approved↗Endocrine↗

Superseded · version 3: Tesamorelin↗

Related names recorded in this version: Egrifta↗

A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We refreshed this profile's label citation to the reviewed SPL version 9, published 2026-07-31. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope. 1

What this version reported

The cited DailyMed label identifies Tesamorelin and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026